within Pharmacolibrary.Drugs.N_NervousSystem.N02A_Opioids.N02AX01_Tilidine;

model Tilidine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.06,
    Cl = 4.8611111111111115e-05,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0036,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.018333333333333333,
    Tlag = 600,
    Vdp = 0.0092,
    k12 = 0.0001575,
    k21 = 0.0001575);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Tilidine</td></tr><tr><td>ATC code:</td><td>N02AX01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>2.5</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Tilidine is a synthetic opioid analgesic used for the relief of moderate to severe pain. It is administered as a racemate but acts through its active metabolite nortilidine. Tilidine is still approved and used in some European countries, such as Germany, but is not commonly available or approved in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N02AX01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Tilidine;
